Transactions of The Showa University Society : The 339 th Meeting 1 ． Multicenter Phase Ⅱ Study of FOLFOX/XELOX and Cetuximab as a First-line Therapy in Patients with Wild-type KRAS/BRAF Metastatic Colorectal Cancer : The FLEET Study

Cargando artículos...

Transactions of The Showa University Society : The 339 th Meeting 1 ． Multicenter Phase Ⅱ Study of FOLFOX/XELOX and Cetuximab as a First-line Therapy in Patients with Wild-type KRAS/BRAF Metastatic Colorectal Cancer : The FLEET Study | InnScience